Method for determining the haemoglobin content of an erythroid cell

Patent metadata

Field	Value
Publication number	US-12345718-B2
Application number	US-202117395969-A
Country	US
Kind code	B2
Filing date	Aug 6, 2021
Priority date	Nov 4, 2016
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

The invention concerns a method for determining, by flow cytometry, the hemoglobin content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the hemoglobin content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or β-thalassemia.

First claim

The invention claimed is:

1. A method for determining, in vitro, a content of at least one hemoglobin Hbx in each erythroid cell of a set of erythroid cells contained in a sample of erythroid cells, comprising the steps of:
a) establishing a standard curve associating fluorescence intensity measured for erythroid cells with at least one hemoglobin Hbx content, using a homogeneous sample of erythroid cells:
b) isolating erythroid cells from the sample;
c) permeabilizing a membrane of the isolated erythroid cells;
d) labeling the at least one hemoglobin Hbx of the erythroid cells obtained in step b) with at least one anti-Hbx antibody conjugated to a fluorochrome capable of emitting a fluorescence;
e) measuring, by flow cytometry, fluorescence intensity (MFI) of each erythroid cell of the set of erythroid cells; and
f) determining the content of the at least one hemoglobin Hbx in each erythroid cell of the set of erythroid cells by comparing the fluorescence intensity of each erythroid cell with the standard curve established in a),

wherein establishing the standard curve comprises:
establishing a calibration straight line which makes it possible to correlate a fluorescence intensity with a fluorophore number;
obtaining a calibration blood sample from patients having an Hbx content that is homogeneous over all of their erythroid cells and having the Hbx labeled with an anti-Hbx antibody conjugated to a fluorophore;
relating a measurement of fluorescence intensity in each erythroid cell in the calibration blood sample to the calibration straight line, such that it is possible to deduce an amount of fluorophore in each erythroid cell;
deducing a number of Hbx molecules of each erythroid cell from the amount of fluorophore in each erythroid cell;
determining a mean content of the at least one hemoglobin Hbx per erythroid cell (MCHbxCo) from the number of Hbx molecules of each erythroid cell; and
establishing the standard curve by associating the MCHbxCo and a measurement of the fluorescence intensity in each erythroid cell in said calibration blood sample.

2. The method as claimed in claim 1 , wherein the membrane of the isolated erythroid cells is fixed before the permeabilization step.

3. The method as claimed in claim 2 , wherein the membrane of the isolated erythroid cells is fixed with sodium azide and/or formaldehyde.

4. The method as claimed in claim 1 , wherein said sample is a blood sample.

5. The method as claimed in claim 4 , wherein the blood sample is a human blood sample.

6. The method as claimed in claim 1 , wherein said fluorochrome is selected from the group consisting of phycoerythrin (PE), fluorescein, isothiocyanate, a derivative thereof or a combination thereof.

7. The method as claimed in claim 1 , wherein the at least one Hbx hemoglobin is at least one first hemoglobin Hbx1, at least one second hemoglobin Hbx2 and at least one n th hemoglobin designated as Hbxn, said method comprising the steps of:
b 1 ) isolating erythroid cells from the sample;
c 1 ) permeabilizing the membrane of the isolated erythroid cells;
d 1 ) labeling the at least one first hemoglobin Hbx1 of the erythroid cells obtained in step b 1 ) with at least one anti-Hbx1 antibody conjugated to a first fluorochrome capable of emitting a first fluorescence; labeling the at least one second hemoglobin Hbx2 of the erythroid cells obtained in step b 1 ) with at least one second anti-Hbx2 antibody conjugated to a second fluorochrome capable of emitting a second fluorescence; labeling the at least one n th hemoglobin Hbxn of the erythroid cells obtained in step b 1 ) with at least one anti-Hbxn antibody conjugated to an n th fluorochrome capable of emitting a n th fluorescence,
e 1 ) measuring, by flow cytometry, fluorescence intensity of each fluorescence emitted by the first, the second, and the n th fluorochrome of each erythroid cell of the set of erythroid cells;
f 1 ) determining the content of the at least one first hemoglobin Hbx1, the at least one second hemoglobin Hbx2, and the at least one n th hemoglobin Hbxn in each erythroid cell of the set of erythroid cells by comparing each of the first, the second, the n th fluorescence intensities measured in step e 1 ) with a first, a second and an n th standard curve associating the measured first, second, and n th fluorescence intensities for an erythroid cell, with content of the at least one first hemoglobin Hbx1, content of the at least one second hemoglobin Hbx2 and content of the at least one n th hemoglobin Hbxn.

8. The method as claimed in claim 1 , wherein the at least one Hbx hemoglobin are n hemoglobins Hbx, designated as Hbxn, said method comprising the steps of:
b 1 ) isolating erythroid cells from the sample;
c 1 ) permeabilizing the membrane of the isolated erythroid cells;
d 1 ) labeling at least one first hemoglobin Hbx1 of the erythroid cells obtained in step b 1 ) with at least one anti-Hbx1 antibody conjugated to a fluorochrome;
e 1 ) measuring, by flow cytometry, the fluorescence intensity (MFI) of each erythroid cell of the set of erythroid cells;
f 1 ) determining the content of the at least one first hemoglobin Hbx1 in each erythroid cell of the set of erythroid cells by comparing the fluorescence intensity of each erythroid cell with a standard curve associating the fluorescence intensity measured for an erythroid cell labeled with at least one anti-Hbx1 antibody with the at least one first hemoglobin Hbx1 content; and
g 1 ) iterating the steps d 1 )-f 1 ) for each of at least one second Hbx2, at least one third Hbx3 and n th Hbxn hemoglobins until the content of the n hemoglobins Hbx in each erythroid cell of the set of erythroid cells is determined.

9. The method as claimed in claim 1 , wherein said at least one anti-Hbx antibody is directed against at least one chain of the at least one hemoglobin Hbx that are selected from the group consisting of α, β, γ, δ, ε ζ chain, glycosylated derivatives thereof, blood disease variants thereof, mutated forms thereof, or a mixture thereof.

10. The method as claimed in claim 1 , wherein said at least one hemoglobin Hbx is selected from the group consisting of HbF, HbA, HbS and a combination thereof.

11. The method as claimed in claim 1 , wherein the membrane of the isolated erythroid cells is permeabilized with sodium dodecyl sulfate.

12. The method as claimed in claim 1 , wherein the content of the at least one hemoglobin Hbx is determined for each erythroid cell of a set of at least 10,000 erythroid cells.

13. The method as claimed in claim 1 , wherein the erythroid cells are red blood cells.

14. A method for determining, in vitro, an amount of erythroid cells transfused into a patient suffering from sickle cell disease, alpha-thalassemia or beta-thalassemia, comprising:
a) determining a content of at least one hemoglobin Hbx selected from the group consisting of HbA, HbF and HbS of each erythroid cell of a set of erythroid cells of a sample of erythroid cells obtained from the patient according to the method of claim 13 ;
b) using results of step a) to determine the amount of erythroid cells transfused into the patient, said transfused erythroid cells having an HbF and/or HbS content substantially equal to zero (=0 pg) and/or a content ratio of HbS/HbF+HbA) substantially equal to zero (=0).

15. An in vitro method for monitoring therapeutic efficacy of a Hematopoietic stem cell transplantation (HSCT) or of a treatment for myelodysplastic syndromes, sickle cell disease or for B-thalassemia, comprising:
a) obtaining a sample containing erythroid cells from a patient having und

Assignees

• Univ Paris Val De Marne
• Assist Publique—Hopitaux De Paris
• Francais Du Sang Ets
• Inst Nat Sante Rech Med
• Hopitaux Paris Assist Publique
• Etablissement Franais Du Sang

Inventors

• Cambot Marie
• Vandemeulebrouck Gaetana
• Noizat Pirenne France
• Bartolucci Pablo
• Rakotoson Marie Georgine
• Galacteros Frédéric
• Hebert Nicolas

Classifications

• G01N2333/805

  Haemoglobins; Myoglobins · CPC title

• G01N2800/22

  Haematology · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N33/723

  Glycosylated haemoglobin · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title